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Abstract
Background: International guidelines recommend long-acting bronchodilators in patients who remain
symptomatic despite adequate treatment with short-acting bronchodilators. The purpose of this study is to
estimate the effect of tiotropium, a long-acting anticholinergic inhalant, on exacerbation and hospitalisation
frequency.
Methods: Electronic databases (Medline, Embase, INAHTA, CRD databases, and the Cochrane Library) were
searched for randomised controlled trials, comparing tiotropium to placebo, or other bronchodilators. Outcomes
were the exacerbation frequency and hospitalisation frequency. Data were pooled using the generic inverse
variance method for continuous outcomes.
Results: Nine studies reported comparisons with placebo (n = 8), ipratropium (short-acting anticholinergic inhalant,
n = 1), and salmeterol (long-acting b2-agonist inhalant, n = 1). Only two studies reported adequate concealment of
allocation. Tiotropium reduces the number of exacerbations per patient year by 0.31 (95% CI 0.46- 0.17) compared
to placebo, and by 0.23 (95% CI 0.31- 0.15) compared to ipratropium. A significant difference in exacerbation
frequency between tiotropium and salmeterol was found (-0.16; 95% CI -0.29 - -0.03) based on approximations of
the results of one study.
The number of hospitalisations is reduced by 0.04 (95% CI 0.08- 0.01) per patient year compared to placebo and by
0.06 (95% CI -0.09 - -0.03) per patient year compared to ipratropium.
Conclusions: Statistically significant but clinically small effects were found for tiotropium compared to placebo and
ipratropium. The comparison with salmeterol is significant for exacerbation frequency but not for hospitalisation
frequency. Publication bias may be present.
Background
Tiotropium (Spiriva®) is a once-daily inhaled long-acting
anticholinergic bronchodilator, used for the maintenance
treatment of COPD. Next to tiotropium, other long-act-
ing bronchodilators are salmeterol, arformoterol and
formoterol, both b2-agonists. International guidelines
recommend long-acting bronchodilators in patients who
remain symptomatic despite adequate treatment with
short-acting bronchodilators [1].
Previous meta-analyses on tiotropium have focused on
the proportion of patients having at least one
exacerbation or COPD-related hospitalisation, and
found that tiotropium significantly lowers both out-
comes compared to placebo or ipratropium[2,3]. How-
ever, results were significantly influenced by the
duration of follow-up[4]. This is not surprising, as
patients may have several events during follow-up and
the likelihood of having at least one exacerbation or
COPD-hospitalisation increases with time[5]. Also, treat-
ment is more likely to reduce the number of exacerba-
tion or COPD-related hospitalisations, rather than
keeping patients totally exacerbation-free and out of the
hospital.
The goal of this study was therefore to estimate the
efficacy of tiotropium on exacerbation frequency and
COPD-related hospitalisation frequency.
* Correspondence: Ann.vandenbruel@kce.fgov.be
1Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium
Full list of author information is available at the end of the article
Van den Bruel et al. BMC Pulmonary Medicine 2010, 10:50
http://www.biomedcentral.com/1471-2466/10/50
© 2010 Van den Bruel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Methods
Literature search
The systematic review was iterative: good-quality sys-
tematic reviews were searched first; the original studies
included in these systematic reviews were complemen-
ted with studies published up until November 2008.
Databases searched were Medline, Embase, INAHTA,
CRD HTA, NICE, the Cochrane Database of Systematic
Reviews (CDSR), and CRD DARE. All search terms used
are listed in table 1.
In addition to published studies, attempts were made
to identify unpublished studies by searching the FDA
http://www.fda.gov/cder/index.html and EMEA websites
http://www.emea.europa.eu/htms/human/epar, clinical
trial registries, contacting known experts in the field and
the manufacturer of tiotropium.
Selection criteria
Randomised controlled trials with a follow-up of at least
12 weeks after randomisation were eligible if they
included a population with stable COPD (no exacerba-
tion one month prior to study entry), and compared tio-
tropium to placebo, ipratropium bromide or long-acting
b2-agonists, on exacerbation and COPD-related hospita-
lisation frequency. Quality of systematic reviews was
assessed using the checklist for systematic reviews of the
Dutch Cochrane Centre http://www.cochrane.nl. Only
reviews with a sensitive search strategy in several data-
bases, and explicit criteria for inclusion and exclusion
were eligible. Original studies were assessed for quality
using the tool described in the Cochrane Handbook of
Systematic Reviews. Original studies were not excluded
based on quality assessment. No language restrictions
were applied.
Eligibility of studies was assessed by two researchers
independently (AVDB, JG). Disagreement was resolved
by consensus.
Analysis
The results of the studies were extracted from the
papers by two independent researchers (AVDB, JG).
Authors and the drug’s manufacturer were contacted in
case of missing data.
Outcomes were the number of exacerbations per
p a t i e n ty e a ra n dt h en u m b e ro fh o s p i t a l i s a t i o n sp e r
patient year.
Data were pooled using the fixed effects model using
the generic inverse-variance approach when no hetero-
geneity was apparent (I
2 ≤ 25%)[6]. In all other cases, a
random effects model was used.
Funnel plots were constructed when five or more stu-
dies were available for one specific comparison and one
particular outcome. Publication bias was statistically
tested using the Egger’st e s tw h e nt e no rm o r es t u d i e s
were available.
All analyses were performed with Review Manager
version 4.2[7].
Results
Included studies
The search for systematic reviews identified five studies
in the CDSR database, 11 studies in Medline, six in the
CRD DARE database and six in the CRD HTA database.
Of these, four were potentially relevant based on title
and abstract[2,3,8,9]. One study was excluded,[9]
because it was not based on a systematic search. In con-
trast, the quality of the two Barr reviews[2,3,8,9] and the
Rodrigo review[2,3,8,9] was very good. However, only
one systematic review included trials with a minimum
duration of 12 weeks,[8] which was thus included in our
study.
The search for original studies was limited to studies
published after the literature search of the Barr review
(2005). Discarding duplicates, a total of 353 studies were
identified in Medline and Embase. After applying
Table 1 Search terms
Evidence synthesis Original studies
CRD
HTA
tiotropium OR BA 679 BR OR spiriva OR oxitropium’
INAHTA tiotropium OR BA 679 BR OR spiriva OR oxitropium’
NICE tiotropium OR BA 679 BR OR spiriva OR oxitropium’
CDSR ’(("tiotropium “[Substance Name]) OR BA 679 BR OR
spiriva OR oxitropium) AND systematic[sb]
CRD
DARE
’(("tiotropium “[Substance Name]) OR BA 679 BR OR
spiriva OR oxitropium) AND systematic[sb]
Medline ’(("tiotropium “[Substance Name]) OR BA 679 BR OR
spiriva OR oxitropium) AND systematic[sb]
(("tiotropium “[Substance Name]) OR BA 679 BR OR spiriva OR oxitropium) AND
((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR
clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation
[MeSH Terms] OR therapeutic use[MeSH Subheading])
Embase ’tiotropium bromide’/exp OR (BA 679 BR) OR ‘spiriva’/exp AND [humans]/lim AND
[2006-2007]/py
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studies were potentially relevant. After assessment in
full text, seven studies were included in the final review
[10-16]. No report on tiotropium was found on the
EMEA site, whereas the FDA published an approval
review in 2004 including six clinical trials, correspond-
ing to three published studies, already captured by our
literature search.
In summary, adding the more recent studies to those
already included in the review by Barr et al., 16 studies
were eligible of which nine reported data that were used
in the analyses presented here (see Figure 1 for flow
chart of literature search). A description of the charac-
teristics of each study is provided in table 2, and quality
assessment is summarised in figure 2.
Overall, studies were very alike with similar inclusion
and exclusion criteria. Patients were at least 40 years
old, had smoked at least 10 pack years and suffered
from moderate to severe COPD. The patients’ mean age
ranged from 63.6 to 77.4 years, the baseline FEV1 ran-
ged from 36% predicted to 51% predicted.
Duration of the study varied between six months (n =
2 ) ,n i n em o n t h s( n=1 ) ,1 2m o n t h s( n=5 ) ,a n d4 8
months (n = 1). This last study was also the largest
study, including 5992 patients[13].
Concomitant medication was specified in all studies
except in one[17]. No study allowed the use of other
anticholinergic medication. All studies allowed short-
acting b2-agonist medication, long-acting b2-agonists
were allowed in four studies, inhalant glucocorticoster-
oids and oral glucocorticosteroids in all studies, with a
maximum dose specified for the latter.
Only two trials[13-15,18] reported adequate conceal-
ment of allocation and most studies did not perform an
intention to treat analysis for all outcomes reported.
Although all studies reported to be double blind, imply-
ing blinding of both patient and treating physician, not
one study described blinded assessment of the outcome.
All studies were sponsored by the pharmaceutical com-
pany marketing tiotropium or the comparator drug, and
analyses were performed by the pharmaceutical com-
pany in two cases.
Meta-analyses
Studies were identified that compared tiotropium
(long-acting anticholinergic) to placebo, ipratropium
(short-acting anticholinergic), and salmeterol (long-
acting b2-agonist).
Exacerbation frequency
Most studies defined exacerbations as at least one or
two new or increased respiratory symptoms, such as
cough, wheeze, dyspnoea, chest congestion, shortness of
breath or sputum production, that necessitate a change
in treatment. Two studies used a purely symptom-based
definition not necessarily leading to a change in treat-
ment[10,19].
For exacerbation frequency, expressed as the number
of exacerbations per patient year, results from nine stu-
dies were available, of which seven compared tiotropium
with placebo and one each with ipratropium and
salmeterol.
The pooled mean difference between tiotropium and
placebo was -0.31 exacerbations per patient year (95%
CI -0.46 - -0.17).(Figure 3) However, heterogeneity was
Figure 1 Flow chart of literature search.
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2 91.2%), mainly caused by one study[10].
This study reported a markedly higher exacerbation fre-
quency in the control group than the other studies (2.46
versus 0.83-1.05 exacerbations per patient year), possibly
caused by the purely symptom-based definition of an
exacerbation. Heterogeneity decreased slightly after
exclusion of this study (I
2 = 79%), with a pooled mean
difference of -0.19 (95% CI -0.28 - -0.09) exacerbations
per patient year.
Compared to ipratropium, tiotropium reduced the
exacerbation frequency with 0.23 (95% CI -0.31 - -0.15)
exacerbation per year. Of note, the two studies compar-
ing tiotropium with salmeterol both reported non-signif-
icant p-values. However, one study[20] did not detail the
exact results, nor were they obtained after contact with
the corresponding author and the drug’s manufacturer
(sponsor of the trial). Consequently, only one study was
included in the analysis, resulting in a mean difference
Table 2 Characteristics of included studies
Study Participants Interventions and duration Notes
Brusasco
2003[17]
1207 patients >40 years, >10 pack years, FEV1 ≤
65% and FVC ≤ 70%
Tiotropium 18 μg
Salmeterol 50 μg
Placebo
6 months
Permitted: not stated
Not permitted: not stated
Casaburi
2002[21]
921 patients ≥ 40 years, ≥ 10 pack years, FEV1 ≤
65%, FVC ≤ 70%
Tiotropium 18 μg
Placebo
1 year
Permitted: Albuterol as needed, stable doses
of theophylline, inhaled glucocorticosteroids
and the equivalent of 10 mg oral
prednisone/day, Not permitted:
anticholinergics and long-acting b2-agonists
Chan
2007[11]
913 patients ≥ 40 years, >10 pack years, FEV1 ≤
60% and FEV1/FVC ≤ 0.70, ≥ 1 exacerbation in
the past 2 years but not within 6 weeks before
study
Tiotropium 18 μg
Placebo
1 year
Permitted: oral steroids at stable dose ≤ 10
mg prednisone/day, stable doses of inhaled
steroids, theophylline, mucolytic, long-acting
b2-agonists; salbutamol for acute relief
Not permitted: inhaled anticholinergics or
oral b2-agonists
Dusser
2006[22]
1010 patients ≥ 40 years, 10 pack years, pre-
bronchodilator FEV1 30-65% and FEV1/SVC ≤
70%, ≥ 1 exacerbation in the last year but not
within 6 weeks prior to the study
Tiotropium 18 μg
Placebo
48 weeks
Permitted: short-acting betagonists,
concomitant use of inhaled or oral steroids
(< 10 mg prednisone equivalent) at stable
dosages, treatment of COPD exacerbations
as deemed necessary
Not permitted: Longacting b2-agonists,
inhaled anticholinergics other than the
study drug and theophylline
Niewoehner 2005[18] 1829 patients ≥ 40 years, ≥ 10 pack-years, FEV1
≤ 60%
FVC ≤ 70%
Tiotropium 18 μg
Placebo
6 months
Permitted: Usual care authorized (including
inhaled corticosteroids and long-acting b-
agonists), antibiotics and systemic steroids
for exacerbations.
Not permitted: other anticholinergic
bronchodilators
Powrie
2007[10]
142 patients ≥ 10 pack years, FEV1 < 80% and
FEV1/FVC < 70%
Tiotropium 18 μg
Placebo
1 year
Permited: usual medication
Not permitted: Anticholinergics other than
the study drug
Tashkin
2008[13]
5992 patients ≥ 40 years, ≥ 10 pack years, FEV1
≤ 70% and FEV1/FVC < 0.7, and perform
satisfactory spirometry
Tiotropium 18 μg
Placebo
4 years
Permitted: usual medication
Not permitted: anticholinergics other than
study drug unless for the treatment of
exacerbations
Tonnel
2008[14]
554 patients ≥ 40 years, > 10 pack years, FEV1 ≤
70% and FEV1/SVC < 0.7
Tiotropium 18 μg
Placebo
9 months
Permitted: salbutamol, stable dosage of
theophylline, mucolytics, ICS and oral
steroids (< 10 mg of prednisone)
Not permitted: b-blockers, antileukotrienes,
oral or inhaled long-acting b2-agonists,
short-acting anticholinergics, or any other
investigational drug
Vincken
2002[19]
535 patients ≥ 40 years, ≥ 10 pack-years, FEV1
≤ 65% and FVC ≤ 70%
Tiotropium 18 μg
Ipratropium 40 mg
52 weeks
Permitted: salbutamol as needed;
theophyllines, inhaled steroids and oral
steroids (at a dose of ≤ 10 mg/day
prednisolone or equivalent) if stable dosage.
Not permitted: other b2-agonists (long or
short acting) and inhaled anticholinergic
medications (other than study drugs)
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-0.03).(Figure 3) Although the paper reported a non-sig-
nificant p-value, we obtained a significant 95% CI, most
likely caused by differences in rounding in the derivation
of the standard error from the p-value. Detailed results
are presented in Figure 4.
COPD-related hospitalisation frequency
Six studies reported sufficient information on hospitali-
sation frequency to be included in the meta-analysis,
five comparing with placebo[11,13,18,21,22] and one
with ipratropium[19].
The difference in hospitalisation frequency with pla-
cebo was -0.04 per patient year (95% CI -0.08 - -0.01),
and with ipratropium -0.06 (95% CI -0.09 - -0.03).(Fig-
ure 3) The frequency in the control group ranged from
0.150-0.250 per patient year. Two studies comparing tio-
tropium with salmeterol reported non-significant p-
values, but no exact results. Again, these could not be
obtained after contacting authors and manufacturer.
(Detailed results Figure 5)
Publication bias
Funnel plots were constructed, but formal testing was
not possible because less than 10 studies were available
for either comparison (Figure 6). The funnel plot on
exacerbations showed asymmetry, suggesting a lack of
studies reporting less favourable results.
Discussion
Tiotropium lowers the number of exacerbations per patient
year significantly by 0.31 (95% CI -0.46 - -0.17) exacerba-
tions/year compared to placebo, and by 0.23 (95% CI -0.31
- -0.15) exacerbations/year compared to iptratropium.
Compared to salmeterol, we found a statistically sig-
nificant difference of 0.16 (95% CI -0.29 - -0.03)
Figure 2 Quality assessment of included studies.
Figure 3 Summary graph of meta-analyses of continuous outcomes.
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Figure 5 Meta-analyses on COPD-related hospitalisation frequency.
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this comparison was reported as non-significant by the
original authors and may be significant in our analyses
because of the approximations we had to use. In addi-
tion, a second study reporting a non-significant differ-
ence but not detailing the results could not be included
in the analyses. For these reasons, this result should be
treated with great caution.
In addition, there was a statistically significant effect
on the number of hospitalisations per patient year of
0.04 (95% CI -0.08 - -0.01) compared to placebo, and
0.06 (95% CI -0.09 - -0.03) compared to ipratropium.
The robustness of these findings is influenced by the
relative moderate quality of the individual studies - only
two studies reported adequate concealment of alloca-
tion- and evidence for publication bias was found.
A recent meta-analysis by Kesten et al. (2009)[23]
comparing tiotropium to placebo found a smaller differ-
ence of -8.90 (95% CI -11.0- (-6.83)) per 100 patient
years. This study is not based on a systematic review of
the literature, but used all phase III and IV studies in
the Boehringer database.
In a recent network meta-analysis, combining both
direct and indirect evidence on different bronchodila-
tors, long-acting anticholinergics, long-acting b2-agonists
and the combination of long-acting b2-agonists and
inhaled corticosteroids were found to significantly
reduce the number of patients with at least one exacer-
bation but without significant differences between them,
[24] which is consistent with our findings.
Our study has some limitations. Publication bias may
be present, by which studies with less favourable results
are not published[25] and consequently not included in
the analyses. Our meta-analysis was further limited by
the fact that not all results were available for inclusion,
although attempts were made to obtain all data. Conse-
quently, the analyses for salmeterol are incomplete. In
addition, the quality of the original studies was not opti-
mal. Especially the uncertainty on allocation conceal-
ment increases the risk of bias. Finally, we were not able
to analyse results according to COPD severity. It might
be possible that some patients would benefit more from
treatment with tiotropium than the general COPD
population. An individual patient data analysis might be
able to explore the influence of patient characteristics
on efficacy.
Conclusion
Patients taking tiotropium experience 0.3 exacerbations
less per year compared to placebo and 0.2 compared to
iptratropium. Compared to salmeterol, tiotropium users
experience 0.16 exacerbations less per year, although
this result should be treated with caution due to incom-
plete results and approximations.
In addition, the number of hospitalisations per patient
year is reduced by 0.04 compared to placebo. No effect
was found compared with salmeterol. The results may
be influenced by flaws in design and publication bias.
Note
The corresponding author (AVDB) confirms that she
had full access to all the data in the study and had final
responsibility for the decision to submit for publication.
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